Innovation Pharmaceuticals Inc (IPIX) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Innovation Pharmaceuticals Inc $0.00, price $0.00, upside -0.6%, quality 26 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Innovation Pharmaceuticals Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective.
Show more
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.
Stock analysis
Innovation Pharmaceuticals Inc (IPIX) currently trades at $0.0009, while our model-based Fair Value estimate is $0.0009, so the stock looks roughly fairly valued today (gap 0.6%).
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 88/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Innovation Pharmaceuticals Inc reported revenue of $18.0K in FY2023 versus $0 in FY2019. Reported net income was −$3.2M in FY2023.
Key figures
Market cap $156K · P/S ratio 8.64 · Return on equity −114% · Return on assets (EBIT) −68.3% · Revenue (TTM) $18.0K · Free cash flow −$2.2M · Net cash $1.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (low confidence).
What moves the price
The share trades about 85% below its 52-week high and 800% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −1%, IPIX screens richer than that median.
Fair Value models
Bear $0.0009Fair Value $0.0009Bull $0.0009
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+0.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−65.1%
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−28.6%
’12
’20
’21
’22
’23
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−572.2% (2012) → −955.6% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2023 is a loss year, no rate is defined from a loss
Compare Innovation Pharmaceuticals Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 576 stocks
Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score28 · Bottom 25%
Fair Value upside−0.6% · Top 25%
Profitability
Return on assets−18.4% · Below median
Operating margin (TTM)0.0% · Above median
Growth and dividend
Revenue growth0.0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Innovation Pharmaceuticals Inc (IPIX) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0009 versus a price of $0.0009, about −1% upside (fairly valued).
What is the fair value of IPIX?
Our model-based fair value for Innovation Pharmaceuticals Inc is $0.0009 (as of Sep 27, 2026), built from audited fundamentals. The current price: $0.0009.
What is the quality score of IPIX?
Innovation Pharmaceuticals Inc has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Innovation Pharmaceuticals Inc (IPIX)?
Our model-based price target is the fair value of $0.0009 (as of Sep 27, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Innovation Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $0.0009, about −1% upside versus a price of $0.0009 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of Innovation Pharmaceuticals Inc (IPIX)?
Innovation Pharmaceuticals Inc reported trailing-twelve-month revenue of about $18.0K (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Innovation Pharmaceuticals Inc (IPIX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Innovation Pharmaceuticals Inc it is $0.0009 per share (as of Sep 27, 2026), against a price of $0.0009. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Innovation Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, IPIX trades above its calculated fair value: price $0.0009, fair value $0.0009, a gap of about −1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IPIX?
No. The price is what the market pays today ($0.0009); the fair value is what the company's own numbers justify ($0.0009). For Innovation Pharmaceuticals Inc the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Innovation Pharmaceuticals Inc worth?
The market values Innovation Pharmaceuticals Inc at about $156K (market capitalisation, as of Sep 27, 2026). Per share that is $0.0009; our models calculate a fair value of $0.0009 per share.
How solid is the balance sheet of Innovation Pharmaceuticals Inc (IPIX)?
Balance-sheet figures for Innovation Pharmaceuticals Inc (as of Sep 27, 2026): return on equity −114.3%. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is IPIX from its 52-week high?
Innovation Pharmaceuticals Inc trades at $0.0009, about 85% below its 52-week high of $0.0060 and 800% above the low of $0.0001 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0009 is for.
Which stocks are comparable to Innovation Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Innovation Pharmaceuticals Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0009, calculated fair value $0.0009 (−1%), Quality Score 26/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IPIX calculated?
We run Innovation Pharmaceuticals Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0009, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Innovation Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Innovation Pharmaceuticals Inc (IPIX)?
The closing price on Oct 1, 2026 was $0.0009. Our model-based fair value is $0.0009, about −1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Innovation Pharmaceuticals Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Innovation Pharmaceuticals Inc
How large is the market capitalisation of Innovation Pharmaceuticals Inc (IPIX)?
The market capitalisation of Innovation Pharmaceuticals Inc is $156K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Innovation Pharmaceuticals Inc (IPIX)?
The price-to-sales ratio of Innovation Pharmaceuticals Inc is 8.64 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Innovation Pharmaceuticals Inc (IPIX)?
The return on equity (ROE) of Innovation Pharmaceuticals Inc is −114% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Innovation Pharmaceuticals Inc (IPIX)?
On an EBIT basis the return on assets of Innovation Pharmaceuticals Inc is −68.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Innovation Pharmaceuticals Inc (IPIX) generate?
The free cash flow of Innovation Pharmaceuticals Inc is −$2.2M (fiscal year 2023). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Innovation Pharmaceuticals Inc (IPIX) hold?
Innovation Pharmaceuticals Inc holds more cash than debt, $1.3M net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Innovation Pharmaceuticals Inc in the live analysis
One click puts Innovation Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026